These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24245577)

  • 1. Phenotypical variation within 22 families with Pompe disease.
    Wens SC; van Gelder CM; Kruijshaar ME; de Vries JM; van der Beek NA; Reuser AJ; van Doorn PA; van der Ploeg AT; Brusse E
    Orphanet J Rare Dis; 2013 Nov; 8():182. PubMed ID: 24245577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Childhood Pompe disease: clinical spectrum and genotype in 31 patients.
    van Capelle CI; van der Meijden JC; van den Hout JM; Jaeken J; Baethmann M; Voit T; Kroos MA; Derks TG; Rubio-Gozalbo ME; Willemsen MA; Lachmann RH; Mengel E; Michelakakis H; de Jongste JC; Reuser AJ; van der Ploeg AT
    Orphanet J Rare Dis; 2016 May; 11(1):65. PubMed ID: 27189384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
    Kroos MA; Pomponio RJ; Hagemans ML; Keulemans JL; Phipps M; DeRiso M; Palmer RE; Ausems MG; Van der Beek NA; Van Diggelen OP; Halley DJ; Van der Ploeg AT; Reuser AJ
    Neurology; 2007 Jan; 68(2):110-5. PubMed ID: 17210890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad variation in phenotypes for common GAA genotypes in Pompe disease.
    Niño MY; In't Groen SLM; de Faria DOS; Hoogeveen-Westerveld M; van den Hout HJMP; van der Ploeg AT; Bergsma AJ; Pijnappel WWMP
    Hum Mutat; 2021 Nov; 42(11):1461-1472. PubMed ID: 34405923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
    Herzog A; Hartung R; Reuser AJ; Hermanns P; Runz H; Karabul N; Gökce S; Pohlenz J; Kampmann C; Lampe C; Beck M; Mengel E
    Orphanet J Rare Dis; 2012 Jun; 7():35. PubMed ID: 22676651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
    Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genotype-phenotype correlation in Pompe disease.
    Kroos M; Hoogeveen-Westerveld M; van der Ploeg A; Reuser AJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):59-68. PubMed ID: 22253258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct disease phenotypes linked to different combinations of GAA mutations in a large late-onset GSDII sibship.
    Sampaolo S; Esposito T; Farina O; Formicola D; Diodato D; Gianfrancesco F; Cipullo F; Cremone G; Cirillo M; Del Viscovo L; Toscano A; Angelini C; Di Iorio G
    Orphanet J Rare Dis; 2013 Oct; 8():159. PubMed ID: 24107549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genetic modifier of symptom onset in Pompe disease.
    Bergsma AJ; In 't Groen SLM; van den Dorpel JJA; van den Hout HJMP; van der Beek NAME; Schoser B; Toscano A; Musumeci O; Bembi B; Dardis A; Morrone A; Tummolo A; Pasquini E; van der Ploeg AT; Pijnappel WWMP
    EBioMedicine; 2019 May; 43():553-561. PubMed ID: 30922962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.
    Oba-Shinjo SM; da Silva R; Andrade FG; Palmer RE; Pomponio RJ; Ciociola KM; S Carvalho M; Gutierrez PS; Porta G; Marrone CD; Munoz V; Grzesiuk AK; Llerena JC; Berditchevsky CR; Sobreira C; Horovitz D; Hatem TP; Frota ER; Pecchini R; Kouyoumdjian JA; Werneck L; Amado VM; Camelo JS; Mattaliano RJ; Marie SK
    J Neurol; 2009 Nov; 256(11):1881-90. PubMed ID: 19588081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational spectrum and genotype-phenotype correlation in Mexican patients with infantile-onset and late-onset Pompe disease.
    Martinez-Montoya V; Sánchez-Sánchez LM; Sandoval-Pacheco R; Castro DMA; Arellano-Valdez CA; Ávila-Rejón CA; Aguilar-Juárez PA; Espino-Pluma M; González-Santillanes CA; Martínez-Segovia RI; Olmos-Morfin D; la Torre OP; Solís-Sánchez I; Espinosa MVM; Villarroel-Cortés CE; Velarde-Félix JS; López-Valdez J; Olaiz-Urbina J; Ricárdez-Marcial E; Vergara-Sánchez I; Radillo-Díaz P; Kazakova E; De la Fuente-Cortez B; Del Carmen Marquez-Quiróz L; Torres-Octavo B; Diaz-Martinez R
    Mol Genet Genomic Med; 2024 Jul; 12(7):e2480. PubMed ID: 38958145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sibling phenotype concordance in classical infantile Pompe disease.
    Smith WE; Sullivan-Saarela JA; Li JS; Cox GF; Corzo D; Chen YT; Kishnani PS
    Am J Med Genet A; 2007 Nov; 143A(21):2493-501. PubMed ID: 17853454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry.
    Reuser AJJ; van der Ploeg AT; Chien YH; Llerena J; Abbott MA; Clemens PR; Kimonis VE; Leslie N; Maruti SS; Sanson BJ; Araujo R; Periquet M; Toscano A; Kishnani PS; On Behalf Of The Pompe Registry Sites
    Hum Mutat; 2019 Nov; 40(11):2146-2164. PubMed ID: 31342611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness.
    Johnson K; Töpf A; Bertoli M; Phillips L; Claeys KG; Stojanovic VR; Perić S; Hahn A; Maddison P; Akay E; Bastian AE; Łusakowska A; Kostera-Pruszczyk A; Lek M; Xu L; MacArthur DG; Straub V
    Orphanet J Rare Dis; 2017 Nov; 12(1):173. PubMed ID: 29149851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
    Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation.
    Liu X; Wang Z; Jin W; Lv H; Zhang W; Que C; Huang Y; Yuan Y
    BMC Med Genet; 2014 Dec; 15():141. PubMed ID: 25526786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel GAA mutations in patients with Pompe disease.
    Turaça LT; de Faria DO; Kyosen SO; Teixeira VD; Motta FL; Pessoa JG; Rodrigues E Silva M; de Almeida SS; D'Almeida V; Munoz Rojas MV; Martins AM; Pesquero JB
    Gene; 2015 Apr; 561(1):124-31. PubMed ID: 25681614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and GAA gene mutation analysis in 21 Chinese patients with classic infantile pompe disease.
    Su X; Sheng H; Huang Y; Li X; Zhang W; Zhao X; Li C; Liu L
    Eur J Med Genet; 2020 Dec; 63(12):103997. PubMed ID: 32711049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.
    Kuperus E; van der Meijden JC; In 't Groen SLM; Kroos MA; Hoogeveen-Westerveld M; Rizopoulos D; Martinez MYN; Kruijshaar ME; van Doorn PA; van der Beek NAME; van der Ploeg AT; Pijnappel WWMP
    PLoS One; 2018; 13(12):e0208854. PubMed ID: 30532252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
    Kishnani PS; Gibson JB; Gambello MJ; Hillman R; Stockton DW; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Day JW; Wang RY; Goldstein JL; An Haack K; Sparks SE; Zhao Y; Hahn SH;
    Genet Med; 2019 Nov; 21(11):2543-2551. PubMed ID: 31086307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.